Oncology

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.

Pharma giant MSD and health-tech innovator Nivi are using an AI chatbot to fight cervical cancer in Asia. Can this model overcome regulatory hurdles and scale?

Strive Health's new CMO and CFO hires signal a strategic acceleration in value-based kidney care, blending clinical innovation with financial AI deployment.

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

German firm NVision wins a top award for POLARIS, a quantum-enhanced MRI platform that shows if cancer therapy is working weeks or months sooner.

Renowned cancer researcher Dr. Morag Park takes the helm at the Gairdner Foundation, a key predictor of Nobel Prizes. What does this strategic move mean for global science?

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

In the chaotic, high-stakes world of pharma tradeshows, success is no longer about free pens. It's about strategy, psychology, and navigating regulations.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

Tri Delta’s 27-year, $185M partnership with St. Jude is more than charity. It's a masterclass in grassroots economic power fueling life-saving innovation.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

A new strategic alliance between a pharma giant and a leading non-profit is deploying a $20M plan to close the deadly prostate cancer survival gap.

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?